Home › Companies › AMPHASTAR PHARMACEUTICALS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2024: 7 items on AMPHASTAR PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2024: 4 elected · 3 approved.
Significant dissent: 2 directors (27.2%, 22.7% against); 1 equity or compensation plan (29.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AMPHASTAR PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are AMPHASTAR PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mary Ziping Luo | 36,539,361 | 3,238,762 | 16,103 | -- | 4,897,137 | 92% | Elected | — |
| Elect Director: Howard Lee | 30,735,084 | 9,041,573 | 17,569 | -- | 4,897,137 | 77% | Elected | — |
| Elect Director: Michael A. Zasloff | 28,934,721 | 10,836,431 | 23,074 | -- | 4,897,137 | 73% | Elected | — |
| Elect Director: Gayle Deflin | 37,568,636 | 2,204,679 | 20,911 | -- | 4,897,137 | 94% | Elected | — |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024 | 44,072,994 | 586,017 | 32,352 | -- | -- | 99% | Approved | — |
| 3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and | 37,859,745 | 1,833,819 | 100,662 | -- | 4,897,137 | 95% | Approved | — |
| 4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan") | 28,069,401 | 11,693,213 | 31,612 | -- | 4,897,137 | 71% | Approved | — |
Source: AMPHASTAR PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 4, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
299 asset managers disclosed a vote on at least one AMPHASTAR PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Gayle Deflin
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gayle Deflin”): 37,568,636 for, 2,204,679 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 16,015,958 for, 1,348,166 against, 4,323 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,200,192 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 830,819 | 0 | 0 | Against |
| Fidelity | 794,105 | 0 | 0 | 0 | For |
| State Street | 634,430 | 1,578 | 0 | 0 | For |
| American Century | 634,419 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 439,674 | 0 | 0 | Against |
| OBERWEIS FUNDS | 394,600 | 0 | 0 | 0 | For |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 283,135 | 0 | 0 | 0 | For |
| Invesco | 268,041 | 0 | 0 | 0 | For |
| Victory Capital | 190,615 | 0 | 0 | 0 | For |
| TIAA | 187,111 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 134,139 | 0 | 0 | 0 | For |
| Brighthouse | 113,112 | 2,376 | 0 | 0 | For |
| Equitable | 104,001 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 101,339 | 0 | 0 | 0 | For |
| MoA Funds Corp | 96,332 | 0 | 0 | 0 | For |
| Jackson National | 80,614 | 13,624 | 0 | 0 | Mixed |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 71,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
77% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Howard Lee
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Howard Lee”): 30,735,084 for, 9,041,573 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 12,077,606 for, 5,286,518 against, 4,323 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 0 | 1,200,192 | 0 | 0 | Against |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 830,819 | 0 | 0 | Against |
| Fidelity | 752,003 | 42,102 | 0 | 0 | Mixed |
| State Street | 628,625 | 7,383 | 0 | 0 | For |
| American Century | 0 | 634,419 | 0 | 0 | Against |
| T. Rowe Price | 0 | 439,674 | 0 | 0 | Against |
| OBERWEIS FUNDS | 0 | 394,600 | 0 | 0 | Against |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 283,135 | 0 | 0 | Against |
| Invesco | 268,041 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 190,615 | 0 | 0 | Against |
| TIAA | 0 | 187,111 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 134,139 | 0 | 0 | Against |
| Brighthouse | 101,048 | 14,440 | 0 | 0 | Mixed |
| Equitable | 104,001 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 101,339 | 0 | 0 | Against |
| MoA Funds Corp | 0 | 96,332 | 0 | 0 | Against |
| Jackson National | 0 | 94,238 | 0 | 0 | Against |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 71,129 | 0 | 0 | Against |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Mary Ziping Luo
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mary Ziping Luo”): 36,539,361 for, 3,238,762 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 15,779,001 for, 1,585,123 against, 4,323 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,200,192 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 830,819 | 0 | 0 | Against |
| Fidelity | 794,105 | 0 | 0 | 0 | For |
| State Street | 9,822 | 626,186 | 0 | 0 | Against |
| American Century | 634,419 | 0 | 0 | 0 | For |
| T. Rowe Price | 439,674 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 394,600 | 0 | 0 | 0 | For |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 283,135 | 0 | 0 | 0 | For |
| Invesco | 268,041 | 0 | 0 | 0 | For |
| Victory Capital | 190,615 | 0 | 0 | 0 | For |
| TIAA | 187,111 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 134,139 | 0 | 0 | 0 | For |
| Brighthouse | 115,488 | 0 | 0 | 0 | For |
| Equitable | 104,001 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 101,339 | 0 | 0 | 0 | For |
| MoA Funds Corp | 96,332 | 0 | 0 | 0 | For |
| Jackson National | 80,614 | 13,624 | 0 | 0 | Mixed |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 71,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: To elect four Class II directors to serve until the Company's 2027 Annual Meeting of Stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Michael A. Zasloff
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Michael A. Zasloff”): 28,934,721 for, 10,836,431 against, per its Form 8-K filed June 4, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 11,105,723 for, 6,258,401 against, 4,323 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 0 | 1,200,192 | 0 | 0 | Against |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 830,819 | 0 | 0 | Against |
| Fidelity | 752,003 | 42,102 | 0 | 0 | Mixed |
| State Street | 4,017 | 631,991 | 0 | 0 | Against |
| American Century | 0 | 634,419 | 0 | 0 | Against |
| T. Rowe Price | 0 | 439,674 | 0 | 0 | Against |
| OBERWEIS FUNDS | 0 | 394,600 | 0 | 0 | Against |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 283,135 | 0 | 0 | Against |
| Invesco | 0 | 268,041 | 0 | 0 | Against |
| Victory Capital | 0 | 190,615 | 0 | 0 | Against |
| TIAA | 0 | 187,111 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 134,139 | 0 | 0 | Against |
| Brighthouse | 101,048 | 14,440 | 0 | 0 | Mixed |
| Equitable | 57,901 | 46,100 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 101,339 | 0 | 0 | Against |
| MoA Funds Corp | 0 | 96,332 | 0 | 0 | Against |
| Jackson National | 0 | 94,238 | 0 | 0 | Against |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 71,129 | 0 | 0 | Against |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
71% Approved · of votes cast
Description as filed by funds: To approve the amendment and restatement of our 2015 Equity Incentive Plan.
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“4. To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan")”): 28,069,401 for, 11,693,213 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4: To approve, the amendment and restatement of the Company's 2015 Equity Incentive Plan (as amended and restated, the "2015 Equity Incentive Plan");”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of AMPHASTAR PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, 1,229,081 against).
The 92 asset managers below reported 11,189,376 for, 4,943,221 against, 6,769 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 0 | 830,819 | 0 | 0 | Against |
| Fidelity | 727,614 | 66,491 | 0 | 0 | Mixed |
| State Street | 4,017 | 631,991 | 0 | 0 | Against |
| American Century | 0 | 634,419 | 0 | 0 | Against |
| T. Rowe Price | 0 | 439,674 | 0 | 0 | Against |
| OBERWEIS FUNDS | 0 | 394,600 | 0 | 0 | Against |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 0 | 283,135 | 0 | 0 | Against |
| Invesco | 0 | 268,041 | 0 | 0 | Against |
| Victory Capital | 0 | 190,615 | 0 | 0 | Against |
| TIAA | 187,111 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 0 | 134,139 | 0 | 0 | Against |
| Brighthouse | 101,048 | 14,440 | 0 | 0 | Mixed |
| Equitable | 57,901 | 46,100 | 0 | 0 | Mixed |
| Columbia Threadneedle | 0 | 101,339 | 0 | 0 | Against |
| MoA Funds Corp | 0 | 96,332 | 0 | 0 | Against |
| Jackson National | 0 | 94,238 | 0 | 0 | Against |
| World Funds Trust | 0 | 74,562 | 0 | 0 | Against |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 0 | 71,129 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 70,402 | 0 | 0 | 0 | For |
Showing the 25 largest of 92 asset managers. All 92 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 96.7% for (June 5, 2023 meeting) ▼ 1.3 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers; and
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“3. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers; and”): 37,859,745 for, 1,833,819 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,200,192 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 830,819 | 0 | 0 | 0 | For |
| Fidelity | 794,105 | 0 | 0 | 0 | For |
| State Street | 633,729 | 2,279 | 0 | 0 | For |
| American Century | 0 | 634,419 | 0 | 0 | Against |
| T. Rowe Price | 439,674 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 394,600 | 0 | 0 | 0 | For |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 283,135 | 0 | 0 | 0 | For |
| Invesco | 268,041 | 0 | 0 | 0 | For |
| Victory Capital | 190,615 | 0 | 0 | 0 | For |
| TIAA | 187,111 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 134,139 | 0 | 0 | 0 | For |
| Brighthouse | 115,488 | 0 | 0 | 0 | For |
| Equitable | 104,001 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 101,339 | 0 | 0 | 0 | For |
| MoA Funds Corp | 96,332 | 0 | 0 | 0 | For |
| Jackson National | 94,238 | 0 | 0 | 0 | For |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 71,129 | 0 | 0 | 0 | For |
Fund voting reports, all 92 managers: 16,672,917 for, 691,050 against, 4,323 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 2,046,395 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,658,019 | 0 | 0 | 0 | For |
| State Street | 1,369,649 | 14,630 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,257,939 | 0 | 0 | 0 | For |
| BlackRock | 1,117,180 | 21,651 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 757,666 | 0 | 0 | 0 | For |
| American Century | 0 | 638,974 | 0 | 0 | Against |
| BOONE CAPITAL MANAGEMENT LLC | 575,547 | 0 | 0 | 0 | For |
| Epoch Investment Partners, Inc. | 573,263 | 0 | 0 | 0 | For |
| T. Rowe Price | 523,079 | 0 | 0 | 0 | For |
| Northern Trust | 453,341 | 1,730 | 0 | 0 | For |
| OBERWEIS ASSET MANAGEMENT INC/ | 398,300 | 0 | 0 | 0 | For |
| Charles Schwab | 358,638 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 333,014 | 0 | 0 | Against |
| Granite Investment Partners, LLC | 311,708 | 0 | 0 | 0 | For |
| Invesco | 291,838 | 0 | 0 | 0 | For |
| BESSEMER INVESTMENT MANAGEMENT LLC | 283,135 | 0 | 0 | 0 | For |
| Point72 | 270,292 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 218,664 | 0 | 0 | 0 | For |
| Victory Capital | 205,246 | 5,864 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 204,198 | 0 | 0 | 0 | For |
| Nuveen | 188,661 | 0 | 0 | 0 | For |
| Bessemer Trust CO of Delaware, N.A. | 178,079 | 0 | 0 | 0 | For |
| Mesirow Institutional Investment Management, Inc. | 50,714 | 126,223 | 0 | 0 | Mixed |
| BESSEMER TRUST Co NATIONAL ASSOCIATION | 163,749 | 0 | 0 | 0 | For |
Institutional-manager reports, all 233 managers: 16,711,383 for, 1,575,091 against, 671 abstained, 58 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 98.6% for (June 5, 2023 meeting) ▲ 0.1 pts
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024;
AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024”): 44,072,994 for, 586,017 against — passed, per its Form 8-K filed June 4, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 94 asset managers below reported 17,363,608 for, 516 against, 4,323 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 3,590,722 | 0 | 0 | 0 | For |
| Vanguard | 2,618,070 | 0 | 0 | 0 | For |
| Federated Hermes | 2,046,394 | 0 | 0 | 0 | For |
| Capitol Series Trust | 1,200,192 | 0 | 0 | 0 | For |
| Neuberger Berman | 1,108,310 | 0 | 0 | 0 | For |
| Dimensional | 830,819 | 0 | 0 | 0 | For |
| Fidelity | 794,105 | 0 | 0 | 0 | For |
| State Street | 635,492 | 516 | 0 | 0 | For |
| American Century | 634,419 | 0 | 0 | 0 | For |
| T. Rowe Price | 439,674 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 394,600 | 0 | 0 | 0 | For |
| Charles Schwab | 342,804 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 283,135 | 0 | 0 | 0 | For |
| Invesco | 268,041 | 0 | 0 | 0 | For |
| Victory Capital | 190,615 | 0 | 0 | 0 | For |
| TIAA | 187,111 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 134,139 | 0 | 0 | 0 | For |
| Brighthouse | 115,488 | 0 | 0 | 0 | For |
| Equitable | 104,001 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 101,339 | 0 | 0 | 0 | For |
| MoA Funds Corp | 96,332 | 0 | 0 | 0 | For |
| Jackson National | 94,238 | 0 | 0 | 0 | For |
| World Funds Trust | 74,562 | 0 | 0 | 0 | For |
| SEI | 74,312 | 0 | 0 | 0 | For |
| BNY Mellon | 71,129 | 0 | 0 | 0 | For |
Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 48,841,343 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 7.35% |
| 2 | Vanguard | 5.36% |
| 3 | Federated Hermes | 4.19% |
| 4 | Capitol Series Trust | 2.46% |
| 5 | Neuberger Berman | 2.27% |
| 6 | Dimensional | 1.70% |
| 7 | Fidelity | 1.63% |
| 8 | State Street | 1.30% |
| 9 | American Century | 1.30% |
| 10 | T. Rowe Price | 0.90% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Federated Hermes | 4.19% |
| 2 | Neuberger Berman | 3.39% |
| 3 | State Street | 2.83% |
| 4 | FULLER & THALER ASSET MANAGEMENT, INC. | 2.58% |
| 5 | BlackRock | 2.33% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.55% |
| 7 | American Century | 1.31% |
| 8 | BOONE CAPITAL MANAGEMENT LLC | 1.18% |
| 9 | Epoch Investment Partners, Inc. | 1.17% |
| 10 | T. Rowe Price | 1.07% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Jack Yongfeng Zhang | 13,435,210 | — | Schedule 13G, filed February 9, 2024 |
| Jack Y. Zhang | 12,774,153 | — | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| Mary Z. Luo | 12,774,153 | — | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| Applied Physics & Chemistry Laboratories, Inc. | 6,827,679 | — | Proxy statement (DEF 14A), proxy filed April 12, 2024 |
| BlackRock | 5,485,057 | — | Form 13F, quarter ended March 31, 2024 |
| Vanguard Group | 2,631,040 | — | Form 13F, quarter ended March 31, 2024 |
| State Street | 1,514,249 | — | Form 13F, quarter ended March 31, 2024 |
| Dimensional Fund Advisors | 1,183,830 | — | Form 13F, quarter ended March 31, 2024 |
| Geode Capital | 866,032 | — | Form 13F, quarter ended March 31, 2024 |
| Renaissance Technologies | 599,100 | — | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 48,841,343 shares outstanding, as reported by AMPHASTAR PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At AMPHASTAR PHARMACEUTICALS INC.'s shareholder meeting held June 3, 2024, in the 2023-2024 proxy season, 299 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 2,413 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — AMPHASTAR PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: AMPHASTAR PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMPHASTAR PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AMPHASTAR PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Proxy Votes Now, “AMPHASTAR PHARMACEUTICALS (AMPH) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/amphastar-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.